Erik Thunnissen, Hans Blaauwgeers, Federica Filipello, Birgit Lissenberg-Witte, Yuko Minami, Masayuki Noguchi, John Le Quesne, Mauro Giulio Papotti, Douglas B Flieder, Giuseppe Pelosi, Irene Sansano, Sabina Berezowska, Aleš Ryška, Luka Brcic, Noriko Motoi, Yukio Nakatani, Christiane Kuempers, Paul Hofman, Veronique Hofman, Vibeke Grotnes Dale, Giulio Rossi, Francesca Ambrosi, Daisuke Matsubara, Yuichi Ishikawa, Birgit Weynand, Fiorella Calabrese, Federica Pezzuto, Izidor Kern, Siobhan Nicholson, Aino Mutka, Sanja Dacic, Mary Beth Beasley, Gianluigi Arrigoni, Wim Timens, Marc Ooft, Mariel Brinkhuis, Nicole Bulkmans, Rieneke Britstra, Willem Vreuls, Kirk D Jones, Jan H von der Thüsen, Hendrik Hager, Sven Perner, David Moore, Diana Gabriela Leonte, Shaimaa Al-Janabi, Andreas Schønau, Olaf Neumann, Klaus Kluck, Iordanis Ourailidis, Markus Ball, Jan Budczies, Daniel Kazdal, Albrecht Stenzinger
{"title":"在生物标志物的支持下,根据世界卫生组织和改进的分类对小肺腺癌侵袭的可重复性研究。","authors":"Erik Thunnissen, Hans Blaauwgeers, Federica Filipello, Birgit Lissenberg-Witte, Yuko Minami, Masayuki Noguchi, John Le Quesne, Mauro Giulio Papotti, Douglas B Flieder, Giuseppe Pelosi, Irene Sansano, Sabina Berezowska, Aleš Ryška, Luka Brcic, Noriko Motoi, Yukio Nakatani, Christiane Kuempers, Paul Hofman, Veronique Hofman, Vibeke Grotnes Dale, Giulio Rossi, Francesca Ambrosi, Daisuke Matsubara, Yuichi Ishikawa, Birgit Weynand, Fiorella Calabrese, Federica Pezzuto, Izidor Kern, Siobhan Nicholson, Aino Mutka, Sanja Dacic, Mary Beth Beasley, Gianluigi Arrigoni, Wim Timens, Marc Ooft, Mariel Brinkhuis, Nicole Bulkmans, Rieneke Britstra, Willem Vreuls, Kirk D Jones, Jan H von der Thüsen, Hendrik Hager, Sven Perner, David Moore, Diana Gabriela Leonte, Shaimaa Al-Janabi, Andreas Schønau, Olaf Neumann, Klaus Kluck, Iordanis Ourailidis, Markus Ball, Jan Budczies, Daniel Kazdal, Albrecht Stenzinger","doi":"10.1016/j.lungcan.2024.108060","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Evaluating invasion in non-mucinous adenocarcinoma (NMA) of the lung is crucial for accurate pT-staging. This study compares the World Health Organization (WHO) with a recently modified NMA classification.</p><p><strong>Materials and methods: </strong>A retrospective case-control study was conducted on small NMA pT1N0M0 cases with a 5-year follow-up. Seventy cases were reviewed by 42 pulmonary pathologists first according to the WHO classification and after tutorial according to a modified classification. A third round was conducted based on feedback from 41 peers of previous rounds. Additionally, orthogonal biomarker analysis was performed.</p><p><strong>Results: </strong>In the first two rounds, 42 pathologists from 13 countries assessed all 70 cases, while 36 pathologists evaluated 41 non-unanimous cases in the third round. Kappa values for invasiveness increased in rounds 1, 2, and 3 to 0.27, 0.45 and 0.62, respectively. In contrast to low variation in total tumor size measurements (6 %), a marked increase in invasive tumor size variation was observed (42 %), which was associated with high uncertainty. In the third round 10 cases were non-invasive, all without recurrence. The modified classification showed in the 3rd round marked reduction of the variation in pT staging compared to the current WHO classification. Proliferation rate, tumor mutational burden, and transcriptomic profiles supported the distinction between invasive cases and non-invasive cases of the modified classification.</p><p><strong>Conclusion: </strong>The modified classification demonstrates essentially higher reproducibility compared to the current WHO classification in NMA. The modified classification proves valuable in identifying low-risk lesions that are entirely non-invasive, and is supported by biomarker analysis.</p>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"199 ","pages":"108060"},"PeriodicalIF":4.5000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers.\",\"authors\":\"Erik Thunnissen, Hans Blaauwgeers, Federica Filipello, Birgit Lissenberg-Witte, Yuko Minami, Masayuki Noguchi, John Le Quesne, Mauro Giulio Papotti, Douglas B Flieder, Giuseppe Pelosi, Irene Sansano, Sabina Berezowska, Aleš Ryška, Luka Brcic, Noriko Motoi, Yukio Nakatani, Christiane Kuempers, Paul Hofman, Veronique Hofman, Vibeke Grotnes Dale, Giulio Rossi, Francesca Ambrosi, Daisuke Matsubara, Yuichi Ishikawa, Birgit Weynand, Fiorella Calabrese, Federica Pezzuto, Izidor Kern, Siobhan Nicholson, Aino Mutka, Sanja Dacic, Mary Beth Beasley, Gianluigi Arrigoni, Wim Timens, Marc Ooft, Mariel Brinkhuis, Nicole Bulkmans, Rieneke Britstra, Willem Vreuls, Kirk D Jones, Jan H von der Thüsen, Hendrik Hager, Sven Perner, David Moore, Diana Gabriela Leonte, Shaimaa Al-Janabi, Andreas Schønau, Olaf Neumann, Klaus Kluck, Iordanis Ourailidis, Markus Ball, Jan Budczies, Daniel Kazdal, Albrecht Stenzinger\",\"doi\":\"10.1016/j.lungcan.2024.108060\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Evaluating invasion in non-mucinous adenocarcinoma (NMA) of the lung is crucial for accurate pT-staging. This study compares the World Health Organization (WHO) with a recently modified NMA classification.</p><p><strong>Materials and methods: </strong>A retrospective case-control study was conducted on small NMA pT1N0M0 cases with a 5-year follow-up. Seventy cases were reviewed by 42 pulmonary pathologists first according to the WHO classification and after tutorial according to a modified classification. A third round was conducted based on feedback from 41 peers of previous rounds. Additionally, orthogonal biomarker analysis was performed.</p><p><strong>Results: </strong>In the first two rounds, 42 pathologists from 13 countries assessed all 70 cases, while 36 pathologists evaluated 41 non-unanimous cases in the third round. Kappa values for invasiveness increased in rounds 1, 2, and 3 to 0.27, 0.45 and 0.62, respectively. In contrast to low variation in total tumor size measurements (6 %), a marked increase in invasive tumor size variation was observed (42 %), which was associated with high uncertainty. In the third round 10 cases were non-invasive, all without recurrence. The modified classification showed in the 3rd round marked reduction of the variation in pT staging compared to the current WHO classification. Proliferation rate, tumor mutational burden, and transcriptomic profiles supported the distinction between invasive cases and non-invasive cases of the modified classification.</p><p><strong>Conclusion: </strong>The modified classification demonstrates essentially higher reproducibility compared to the current WHO classification in NMA. The modified classification proves valuable in identifying low-risk lesions that are entirely non-invasive, and is supported by biomarker analysis.</p>\",\"PeriodicalId\":18129,\"journal\":{\"name\":\"Lung Cancer\",\"volume\":\"199 \",\"pages\":\"108060\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-12-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.lungcan.2024.108060\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.lungcan.2024.108060","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers.
Objectives: Evaluating invasion in non-mucinous adenocarcinoma (NMA) of the lung is crucial for accurate pT-staging. This study compares the World Health Organization (WHO) with a recently modified NMA classification.
Materials and methods: A retrospective case-control study was conducted on small NMA pT1N0M0 cases with a 5-year follow-up. Seventy cases were reviewed by 42 pulmonary pathologists first according to the WHO classification and after tutorial according to a modified classification. A third round was conducted based on feedback from 41 peers of previous rounds. Additionally, orthogonal biomarker analysis was performed.
Results: In the first two rounds, 42 pathologists from 13 countries assessed all 70 cases, while 36 pathologists evaluated 41 non-unanimous cases in the third round. Kappa values for invasiveness increased in rounds 1, 2, and 3 to 0.27, 0.45 and 0.62, respectively. In contrast to low variation in total tumor size measurements (6 %), a marked increase in invasive tumor size variation was observed (42 %), which was associated with high uncertainty. In the third round 10 cases were non-invasive, all without recurrence. The modified classification showed in the 3rd round marked reduction of the variation in pT staging compared to the current WHO classification. Proliferation rate, tumor mutational burden, and transcriptomic profiles supported the distinction between invasive cases and non-invasive cases of the modified classification.
Conclusion: The modified classification demonstrates essentially higher reproducibility compared to the current WHO classification in NMA. The modified classification proves valuable in identifying low-risk lesions that are entirely non-invasive, and is supported by biomarker analysis.
期刊介绍:
Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.